Eli Lilly says its potential gene therapy 'restored hearing' in 11-year-old boy
An 11-year-old boy who received Eli Lilly’s experimental gene therapy for hearing loss last October showed signs of restored hearing 30 days after treatment, the pharma giant announced on Tuesday.
The therapy, dubbed AK-OTOF, is designed to deliver a functional copy of a gene called otoferlin. Without otoferlin, auditory signals received by the ear aren’t transmitted to the brain. Lilly estimates that 200,000 people worldwide experience hearing loss caused by mutations to otoferlin.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.